despit
import
advanc
field
lung
transplant
last
decad
surviv
lung
transplant
recipi
remain
significantli
lower
solid
organ
transplant
sot
outcom
believ
due
part
exposur
allograft
extern
environ
inhal
environment
agent
infecti
organ
trigger
immunolog
mediat
deleteri
effect
lung
function
communityacquir
respiratori
virus
carv
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
influenza
b
flu
adenoviru
adv
human
metapneumoviru
hmpv
coronaviru
rhinoviru
rv
increasingli
recogn
import
pathogen
lung
transplant
recipi
studi
suggest
carv
may
immedi
longterm
advers
effect
allograft
perform
viral
infect
gener
direct
cytopath
damag
lung
epithelium
provok
indirect
injuri
stimul
inflammatori
cytokin
cell
activ
alloreact
respons
viral
infect
lead
substanti
morbid
mortal
lung
transplant
recipi
develop
potent
antivir
agent
sensit
molecular
techniqu
detect
infect
comprehens
manag
strategi
paramount
reduc
complic
carv
follow
lung
transplant
review
discuss
individu
pathogen
incid
diseas
role
new
diagnost
techniqu
treatment
regimen
establish
viral
infect
prevent
strategi
potenti
impact
carv
acut
chronic
allograft
reject
carv
divers
group
virus
belong
sever
famili
includ
paramyxovirida
rsv
piv
hmpv
orthomyxovirida
flu
b
picornavirida
rv
coronavirida
coronaviru
adenovirida
adv
singlestrand
rna
virus
except
adenoviru
doublestrand
dna
viru
viral
transmiss
follow
direct
inocul
infect
secret
fomit
largeparticl
aerosol
upper
respiratori
tract
rhinoviru
piv
typic
occur
yearround
remain
carv
usual
season
peak
octob
april
report
incid
carv
lung
transplant
patient
rang
actual
incid
howev
may
underestim
due
insensit
diagnost
method
report
lung
transplant
recipi
lung
allograft
may
particularli
suscept
viral
infect
due
immunosuppress
cough
inhibit
denerv
transplant
lung
impair
mucociliari
clearanc
compromis
lymphat
drainag
multipl
studi
demonstr
differ
carv
infect
rate
base
demograph
mainten
immunosuppress
regimen
time
transplant
infect
variabl
develop
within
day
year
posttransplant
one
singlecent
retrospect
studi
indic
diagnos
piv
infect
develop
within
day
lung
transplant
earli
onset
carv
ill
suggest
donor
organ
transmiss
conceiv
similar
immunocompet
host
carv
infect
caus
spectrum
diseas
process
includ
rhiniti
pharyng
tracheobronch
bronchiol
pneumonia
progress
lower
respiratori
tract
infect
lrti
report
occur
infect
recipi
mani
studi
defin
lrti
variabl
combin
follow
sign
symptom
infiltr
thorac
imag
posit
bronchoalveolar
lavag
bal
specimen
viru
decreas
hypoxemia
wheez
kumar
et
al
report
outcom
asymptomat
versu
symptomat
patient
significantli
differ
patient
symptomat
commonli
exhibit
cough
fever
nasal
congest
wheez
hypoxemia
coryza
dyspnea
mortal
lung
transplant
recipi
follow
carv
infect
rang
chest
radiograph
typic
nonspecif
find
includ
chang
baselin
diffus
interstiti
infiltr
focal
alveolar
consolid
chest
ct
scan
lung
transplant
recipi
infect
rsv
reveal
evid
airway
diseas
includ
air
trap
groundglass
infiltr
airspac
consolid
bronchial
dilat
bronchial
wall
thicken
bronchiol
adenovir
infect
may
frequent
associ
progress
pulmonari
opac
serial
ct
scan
show
persist
bronchial
thicken
airtrap
mosaic
lung
attenu
manifest
bronchiol
obliteran
syndrom
bo
chronic
reject
carv
infect
may
advers
affect
pulmonari
physiolog
two
studi
rsv
caus
signific
decreas
within
nineti
day
infect
recent
prospect
analysi
inclus
recogn
carv
reveal
fall
ensu
onethird
lung
transplant
recipi
fall
persist
major
patient
support
associ
carv
bo
prompt
accur
diagnosi
carv
infect
critic
ongo
manag
lung
transplant
recipi
given
concern
associ
acut
chronic
reject
standard
diagnost
test
includ
immunofluoresc
antibodi
assay
dfa
respiratori
cultur
perform
nasal
wash
nasal
swab
bal
specimen
compar
pediatr
patient
yield
obtain
upper
respiratori
tract
sampl
adult
may
inferior
due
decreas
viral
burden
shed
nasal
passag
analysi
bal
shown
improv
sensit
result
viral
cultur
also
take
mani
day
posit
result
return
delay
initi
antivir
therapi
risk
transmiss
ill
immunosuppress
patient
older
form
test
typic
identifi
fewer
number
carv
newer
test
rapid
respiratori
viral
cultur
rrv
antigen
detect
eia
allow
faster
precis
result
present
time
howev
commerci
avail
antigen
detect
kit
exist
rhinoviru
coronaviru
multiplex
polymeras
chain
reaction
pcr
analysi
rapidli
becom
prefer
test
viral
diagnost
immunocompromis
host
diagnost
test
allow
detect
common
respiratori
viral
type
singl
assay
weinberg
et
al
found
pcr
improv
sensit
viral
detect
versu
rrv
cultur
eia
kumar
et
al
also
demonstr
higher
sensit
pcr
compar
dfa
viral
cultur
one
drawback
pcr
discern
viabl
kill
viru
cours
antivir
therapi
clinician
must
reli
rrv
tradit
viral
cultur
determin
treatment
efficaci
influenza
virus
carv
specif
fdaapprov
therapi
exist
influenza
typic
caus
influenza
b
viru
annual
pandem
flu
subtyp
note
caus
vari
degre
graft
dysfunct
lung
transplant
recipi
review
australian
pandem
lung
transplant
recipi
reveal
overal
incid
patient
allograft
dysfunct
death
current
antivir
therapi
flu
direct
protein
contain
viral
envelop
amantan
inhibitor
consist
amantadin
rimantidin
block
ion
channel
within
membran
unfortun
efficaci
class
drug
limit
due
rapid
develop
antivir
resist
lack
effect
flub
neuraminidas
inhibitor
oseltamavir
tamiflu
zanamivir
relenza
peramivir
inhibit
releas
new
viru
host
cell
prevent
spread
viru
accord
center
diseas
control
recommend
zanamivir
reserv
oseltamivirresist
strain
flu
inhal
form
medic
use
caution
patient
seriou
preexist
respiratori
diseas
due
potenti
side
effect
cough
bronchospasm
even
death
inhal
zanamivir
contraind
intraven
form
approv
use
emerg
situat
intraven
peramivir
also
approv
emerg
use
author
similar
inhibitor
immunocompromis
patient
shown
higher
resist
neuraminidas
inhibitor
possibl
due
prolong
viral
shed
lead
select
resist
strain
gener
earli
initi
antivir
therapi
influenza
reduc
risk
develop
viral
pneumonia
versu
death
versu
investig
therapi
flu
develop
report
use
immunosuppress
patient
favipiravir
toyama
chemic
fludas
nexbio
inc
demonstr
vitro
vivo
effect
flu
includ
avian
strain
also
publish
data
use
rnainterferencebas
rnai
antivir
agent
prevent
treatment
flu
inactiv
kill
viral
vaccin
option
transplant
recipi
efficaci
vaccin
like
decreas
due
immun
suppress
studi
issa
et
al
patient
protect
antibodi
titer
higher
live
attenu
nasal
administ
vaccin
flumist
contraind
transplant
patient
due
risk
infect
current
fdaapprov
antivir
medic
vaccin
treatment
piv
ribavirin
shown
vitro
vivo
activ
piv
case
report
use
combin
ivig
methylprednisolon
reveal
slower
declin
lung
heartlung
transplant
recipi
compar
placebo
fludas
nexbio
inc
investig
drug
flu
inhibit
piv
infect
vitro
anim
model
addit
case
report
success
use
inhal
form
lung
transplant
recipi
proven
piv
infect
agent
disabl
airway
epitheli
receptor
remov
sialic
acid
moieti
therebi
prevent
viral
attach
antivir
rnaibas
therapeut
target
piv
also
investig
live
attenu
vaccin
develop
prevent
therapi
howev
live
variant
viru
inocul
render
unsaf
immunosuppress
patient
could
acquir
seriou
infect
vaccin
aerosol
ribavirin
licens
treatment
rsv
bronchiol
infant
children
use
human
monoclon
antibodi
palivizumab
synagi
also
associ
decreas
hospit
pediatr
patient
although
limit
data
treat
rsv
follow
lung
transplant
mani
expert
recommend
administr
inhal
ribavirin
ivig
methylprednisolon
palivizumab
vilchez
et
al
report
decreas
incid
postrsv
bo
use
inhal
ribavirin
compar
incid
without
therapi
anoth
studi
hematopoiet
stem
cell
transplant
patient
rsv
pneumonia
reveal
mortal
combin
therapi
ivig
steroid
ribavirin
palivizumab
versu
untreat
experienc
delay
treatment
exact
mechan
action
ribavirin
unclear
drug
synthet
nucleosid
analog
may
interfer
express
viral
mrna
protein
translatori
level
may
also
incorpor
rsv
rna
viral
genom
lead
lethal
mutagenesi
immunoglobulin
therapi
neutral
rsv
antibodi
titer
palivizumab
direct
fusion
protein
rsv
use
altern
rout
ribavirin
administr
may
decreas
respiratori
side
effect
minim
toxic
exposur
healthcar
worker
reduc
treatment
cost
examin
prospect
analysi
glanvil
et
al
suggest
intraven
ribavirin
therapi
oral
steroid
lung
transplant
recipi
safe
cost
effect
two
studi
found
use
oral
ribavirin
either
prevent
postrsv
bo
year
treatment
significantli
improv
graft
function
recoveri
paramyxovir
infect
investig
medic
rsv
treatment
also
develop
rnai
drug
investig
zamora
et
al
random
control
trial
twentyfour
lung
transplant
recipi
inhal
medic
result
lower
symptom
score
significantli
lower
rate
new
onset
bo
nineti
day
compar
placebo
antivir
isoprenyl
inhibitor
like
lovastatin
could
also
efficaci
rsv
treatment
inhibit
viral
replic
cell
cell
fusion
human
metapneumoviru
recogn
carv
incid
hmpv
infect
lung
transplant
patient
report
rang
multipl
studi
describ
associ
hmpv
infect
acut
reject
ar
incid
recent
recogn
carv
treatment
option
hmpv
less
well
studi
specif
therapi
hmpv
exist
ribavirin
shown
vitro
activ
viru
consist
member
paramyxovirida
famili
publish
case
report
indic
success
treatment
hmpv
intraven
ribavirin
monotherapi
conjunct
ivig
steroid
lung
transplant
recipi
novel
research
evalu
possibl
synthet
interfer
rna
rnai
therapeut
agent
hmpv
demonstr
complet
inhibit
viral
replic
vitro
partial
inhibit
murin
model
definit
therapi
exist
adv
tradit
therapi
includ
support
care
decreas
immunosuppress
role
antivir
agent
remain
unproven
sever
case
report
describ
vitro
activ
adv
ribavirin
center
util
inhal
ribavirin
ivig
three
patient
adv
pneumonia
two
patient
improv
five
day
treatment
third
patient
preexist
bo
develop
respiratori
failur
die
nonpublish
data
recent
use
cidofovir
treatment
adenovir
diseas
describ
reduc
mortal
pediatr
lung
transplant
adult
hematopoiet
stem
cell
transplant
recipi
lipid
conjug
cidofovir
also
evalu
case
seri
immunocompromis
patient
limit
success
agent
benefit
less
nephrotox
cidofovir
may
side
effect
diarrhea
proven
antivir
therapi
avail
treatment
rv
perhap
common
caus
carv
infect
healthi
immunocompromis
adult
pleconaril
bind
rhinovir
capsid
prevent
viral
uncoat
attach
lead
decreas
replic
studi
potenti
pharmacotherapeut
option
investig
trial
immunocompet
adult
reveal
shorter
time
allevi
ill
decreas
frequenc
posit
cultur
nasal
secret
treatment
report
util
pleconaril
lung
transplant
recipi
rhinovir
pneumonia
limit
proof
efficaci
still
lack
addit
concern
substanti
number
clinic
isol
limit
sensit
pleconaril
exhibit
high
effect
inhibitori
concentr
mani
studi
support
associ
carv
ar
carv
may
play
import
role
ar
upregul
cytokin
product
activ
cell
result
inflammatori
allopath
respons
within
graft
prospect
analysi
kumar
et
al
primari
endpoint
decreas
least
evid
least
reject
biopsi
occur
lung
transplant
recipi
versu
recipi
without
carv
infect
anoth
report
found
lung
transplant
recipi
diagnos
carv
infect
fall
greater
third
studi
indic
patient
transbronchi
biopsi
time
infect
evid
acut
allograft
reject
studi
howev
return
baselin
within
week
month
thu
associ
carv
persist
declin
bo
unclear
murin
orthotop
lung
transplant
model
infect
piv
type
result
persist
epitheli
injuri
lumin
obliter
chronic
bronchiolar
scar
sever
human
investig
howev
yield
conflict
result
regard
risk
develop
bo
carv
infect
studi
vari
number
virus
research
sampl
size
sensit
methodolog
use
frequenc
sampl
collect
make
difficult
draw
specif
conclus
singlecent
retrospect
studi
involv
predominantli
upperrespiratori
tract
infect
urti
find
connect
rsv
piv
bo
although
virus
contribut
longterm
dysfunct
death
patient
anoth
review
multipl
cohort
found
pool
incid
bo
viru
posit
case
versu
viru
neg
case
statist
signific
sever
retrospect
studi
howev
support
associ
carv
chronic
reject
review
cohort
studi
vilchez
et
al
report
rate
bo
follow
carv
infect
lung
transplant
recipi
rang
depend
type
viru
bill
et
al
suggest
recipi
lrti
due
carv
rel
risk
develop
highgrad
bo
recipi
infect
within
first
six
month
posttranspl
like
acquir
highgrad
bo
support
independ
connect
carv
infect
bo
publish
retrospect
studi
khalifah
et
al
analysi
indic
carv
infect
lung
transplant
doubl
risk
develop
bo
stage
lrti
risk
subsequ
progress
bo
tripl
current
prospect
analys
also
provid
inconsist
data
relationship
carv
infect
bo
lung
transplant
recipi
multicent
studi
milston
et
al
predominantli
follow
patient
urti
one
year
post
respiratori
infect
find
differ
rate
bo
develop
infect
noninfect
recipi
rsv
piv
contrast
singlecent
investig
gottlieb
et
al
patient
exhibit
lrtisymptom
indic
symptomat
carv
infect
increas
probabl
new
onset
bo
progress
risk
particularli
increas
follow
piv
infect
third
prospect
analysi
evalu
nineteen
carv
threeyear
period
postinfect
report
incid
bo
one
year
lung
transplant
recipi
frequent
expos
carv
virus
becom
increasingli
recogn
import
caus
morbid
mortal
lung
transplant
recipi
upper
lower
respiratori
tract
infect
shown
occur
carv
newer
highli
sensit
diagnost
techniqu
led
improv
diagnost
accuraci
result
although
studi
evalu
impact
carv
short
long
term
allograft
function
heterogen
variou
limit
major
investig
support
direct
relationship
ar
carv
infect
also
support
associ
carv
infect
bo
sinc
ar
establish
risk
factor
bo
present
time
proven
treatment
carv
infect
lung
transplant
recipi
extrem
limit
combin
therapi
ribavirin
report
activ
rsv
piv
hmpv
adv
altern
medic
treatment
paramyxovirida
infect
well
flu
adv
rv
develop
insight
diseas
pathogenesi
carv
infect
futur
prospect
studi
warrant
order
hasten
implement
novel
manag
strategi
decreas
risk
bo
major
caus
longterm
graft
failur
lung
transplant
recipi
